Vault-13

Aquilo Capital Management, LLC

SAN FRANCISCO, CA · CIK 1591986 · 13F filing filed 2022-08-15

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$237.3m reported value -30.7% vs Q1 2022
12positions
95.8%in top 10
0 new 9 added 2 reduced 0 sold out vs Q1 2022

Options: 0 call positions (— notional), 1 put positions ($55.7m notional) – listed below, not included above.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ARROWHEAD PHARMACEUTICALS IN COM ARWR ARWR 1,198,515 $42.2m17.78% 17.78% AddedShares held: Q3 2021 527.9k, Q4 2021 700.4k, Q1 2022 1.0m, Q2 2022 1.2m +151.1k +151,075 14.4%
2 BLUEPRINT MEDICINES CORP COM BPMC BPMC 716,539 $36.2m15.25% 15.25% ReducedShares held: Q3 2021 521.7k, Q4 2021 645.5k, Q1 2022 781.5k, Q2 2022 716.5k -65.0k -65,000 -8.3%
3 MERUS N V COM MRUS MRUS 1,477,109 $33.4m14.09% 14.09% AddedShares held: Q3 2021 0, Q4 2021 896.5k, Q1 2022 1.3m, Q2 2022 1.5m +215.6k +215,575 17.1%
4 ARVINAS INC COM ARVN ARVN 771,745 $32.5m13.69% 13.69% AddedShares held: Q3 2021 354.7k, Q4 2021 563.5k, Q1 2022 695.2k, Q2 2022 771.7k +76.5k +76,498 11.0%
5 REGENXBIO INC COM RGNX RGNX 1,167,684 $28.8m12.15% 12.15% AddedShares held: Q3 2021 839.1k, Q4 2021 1.0m, Q1 2022 1.1m, Q2 2022 1.2m +49.0k +49,000 4.4%
6 UNIQURE NV SHS QURE QURE 971,490 $18.1m7.63% 7.63% AddedShares held: Q3 2021 1.3m, Q4 2021 676.2k, Q1 2022 901.5k, Q2 2022 971.5k +70.0k +70,000 7.8%
7 AMRYT PHARMA PLC SPONSORED ADS SPONSORED ADS 1,866,652 $13.0m5.50% 5.50% AddedShares held: Q3 2021 1.4m, Q4 2021 1.6m, Q1 2022 1.6m, Q2 2022 1.9m +226.7k +226,652 13.8%
8 ARGENX SE SPONSORED ADR ARGX ARGX 24,000 $9.1m3.83% 3.83% UnchangedShares held: Q3 2021 22.2k, Q4 2021 22.2k, Q1 2022 24.0k, Q2 2022 24.0k
9 PIERIS PHARMACEUTICALS INC COM COM 3,736,280 $7.0m2.94% 2.94% AddedShares held: Q3 2021 3.2m, Q4 2021 3.2m, Q1 2022 3.7m, Q2 2022 3.7m +27.4k +27,398 0.7%
10 GENMAB A/S SPONSORED ADS GMAB GMAB 214,848 $7.0m2.94% 2.94% AddedShares held: Q3 2021 127.5k, Q4 2021 127.5k, Q1 2022 167.5k, Q2 2022 214.8k +47.3k +47,348 28.3%
11 4D MOLECULAR THERAPEUTICS IN COM FDMT FDMT 861,607 $6.0m2.53% 2.53% ReducedShares held: Q3 2021 1.1m, Q4 2021 1.5m, Q1 2022 1.8m, Q2 2022 861.6k -893.9k -893,899 -50.9%
12 SPERO THERAPEUTICS INC COM SPRO SPRO 5,321,231 $3.9m1.66% 1.66% AddedShares held: Q3 2021 4.6m, Q4 2021 5.0m, Q1 2022 5.3m, Q2 2022 5.3m +39.7k +39,727 0.8%

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
SPDR SER TR XBI · Put XBIPut 750,000 $55.7m750.0k shares New

Trades reported as a company insider in Q2 2022

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2022-04-26 SPERO THERAPEUTICS INC 10% owner · See Footnotes SPRO Bought 39,727 $208.2k39.7k shares +1%